Oncology – Gynecologic
Systematic Review | Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
8 Aug, 2023 | 13:11h | UTCPegylated liposomal doxorubicin for relapsed epithelial ovarian cancer – Cochrane Library
RCT | Niraparib after first-line platinum-based chemotherapy extends PFS vs. placebo in newly diagnosed advanced ovarian cancer
31 Jul, 2023 | 13:58h | UTCSee also: Visual Abstract
Commentary: Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer – The ASCO Post
Review | Radiomics-based fertility-sparing treatment in endometrial carcinoma
24 Jul, 2023 | 13:00h | UTC
FIGO staging of endometrial cancer: 2023
29 Jun, 2023 | 13:53h | UTCFIGO staging of endometrial cancer: 2023 – Gynecology & Obstetrics
#ASCO23 – RCT | Simple hysterectomy shown non-inferior to radical hysterectomy in low-risk early-stage cervical cancer
5 Jun, 2023 | 13:43h | UTCCommentaries:
Clinical Trial Update | Olaparib plus bevacizumab first-line maintenance in ovarian cancer
5 Jun, 2023 | 13:07h | UTCOriginal Study: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer – New England Journal of Medicine
Clinical Trial Update | Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer
15 May, 2023 | 12:43h | UTCOriginal Article: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Enhanced recovery after surgery (ERAS) society guidelines for gynecologic oncology: addressing implementation challenges
5 May, 2023 | 14:53h | UTC
Review | Cancer treatment-related cardiovascular toxicity in gynecologic malignancies
26 Apr, 2023 | 14:14h | UTC
Commentary on Twitter
A comprehensive #JACCCardioOnc state-of-the-art review of cancer treatment-related cardiovascular toxicity in gynecologic malignancies: https://t.co/24sFcHfyPf#GynOnc #GynCSM #CardioOnc #cardiotoxicity #CardioTwitter @emorywomenheart @sdent_duke pic.twitter.com/kzqILRzuwz
— JACC Journals (@JACCJournals) April 20, 2023
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
SR | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
25 Apr, 2023 | 14:22h | UTCAngiogenesis inhibitors for the treatment of epithelial ovarian cancer – Cochrane Library
M-A | Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer
17 Apr, 2023 | 12:59h | UTC
Review | Comprehensive care of women with genetic predisposition to breast and ovarian cancer
5 Apr, 2023 | 13:32h | UTC
RCT | Pembrolizumab plus chemotherapy in advanced endometrial cancer
3 Apr, 2023 | 13:48h | UTCPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Original Article: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer https://t.co/dTyV1zTO0I
#SGOMtg @SGO_org pic.twitter.com/R3FDom8pVY— NEJM (@NEJM) March 29, 2023
RCT | Dostarlimab for primary advanced or recurrent endometrial cancer
3 Apr, 2023 | 13:46h | UTCDostarlimab for Primary Advanced or Recurrent Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary:
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer – OncLive
Consensus Statement | Management of vaginal intraepithelial neoplasia
28 Mar, 2023 | 14:37h | UTC
Cohort Study | Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer
2 Mar, 2023 | 12:56h | UTCCommentary: Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment – HealthDay
Commentary on Twitter
Use of tamoxifen as an adjuvant hormone therapy for breast cancer was associated with an increased risk of endometrial polyps, hyperplasia, carcinoma, and other uterine cancers in Korean premenopausal women. https://t.co/JqnKjemjoW
— JAMA Network Open (@JAMANetworkOpen) November 29, 2022
Recent advances in the classification of gynecological tract tumors: updates from the 5th edition of the WHO “Blue Book”
16 Feb, 2023 | 14:35h | UTC
M-A | Risk of endometrial cancer in postmenopausal women in relation to ultrasonographic endometrial thickness
8 Feb, 2023 | 12:21h | UTCRisk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
Commentary on Twitter
AJOG Systematic Review: Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis https://t.co/uxPx8Jr160 pic.twitter.com/LugkrnKmjr
— AJOG (@AJOG_thegray) December 30, 2022
Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma
27 Jan, 2023 | 12:01h | UTC
Commentary on Twitter
Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) December 6, 2022
Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions
24 Jan, 2023 | 14:05h | UTCOriginal Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N
— Radiology (@radiology_rsna) November 23, 2022
Review | Advances in the diagnosis and early management of gestational trophoblastic disease
19 Jan, 2023 | 14:08h | UTCAdvances in the diagnosis and early management of gestational trophoblastic disease – BMJ Medicine
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ
Review | Endometrial cancer: molecular classification and future treatments.
16 Dec, 2022 | 13:20h | UTCEndometrial cancer: molecular classification and future treatments – BMJ Medicine
Commentary on Twitter
The latest #review by Bradley Corr and colleagues concludes that the development of molecular analysis combined with novel agents and new drug classes have revolutionised #precisionmedicine for patients with endometrial #cancer. Read now ▶️ https://t.co/TaNgrM2EWl#MedTwitter pic.twitter.com/GexXdLzlQH
— BMJMedicine (@BMJMedicine) December 9, 2022
RCT | Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer.
14 Dec, 2022 | 14:44h | UTCOptimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
? LESS IS MORE – Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer
? 15 months remains standard of care ➡️ https://t.co/nKwehjxnHu #gyncsm pic.twitter.com/9DBInZv1t0— Journal of Clinical Oncology (@JCO_ASCO) December 4, 2022